Watson Biosimilar Tie Up With Itero Plays Into Women's Health Expertise
This article was originally published in The Pink Sheet Daily
Watson licenses rights to a recombinant follicle stimulating hormone in preclinical development that would reference Merck-Serono's infertility drug Gonal-f.
You may also be interested in...
Late-stage pipeline is dominated by follicle stimulating hormones, split between “biobetters” and biosimilars. Next-generation oxytocin antagonists are leading candidates for the next novel entities in infertility.
IMS Health official says the biologic and biosimilar markets are looming growth areas as small-molecule opportunities decline, but questions about the abbreviated biosimilar pathway linger.
Branded drugs may earn only a fraction of Watson's generics, but firm sees overlapping opportunity in urology and women's health care.